Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

The rise in Netflix stock price doesn’t mean the opportunity for investors is over, a Bernstein analyst argued on Friday.

Nvidia stock rose modestly early Friday as investors digested a raft of mixed news over the past few days. Shares were up 0.1 ...

Our opinions are our own. Most credit cards tack an extra charge on purchases made outside the U.S. If you're planning to travel abroad, you'll want a card without foreign transaction fees ...

While rooting for the Chiefs during their first playoff game of the season, Shields and Donna teamed up to participate in a GSK campaign called ... Please enter a name. Please enter a valid ...

Other drugs on the list include Pfizer’s cancer drugs Ibrance and Xtandi, GSK’s asthma and chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta, Teva’s Huntington’s ...

Perhaps mRESVIA can do a little better next season, but I don't expect it to outperform GSK plc's (GSK ... that key readout isn't probably on the cards in 2025, certainly not early 2025.

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...